Anti-RGMA Antibody (Elezanumab)
Catalog No.
F2025
Anti-RGMA Antibody (Elezanumab)
Featured Products
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets the repulsive guide molecule A (RGMa). Elezanumab effectively inhibits RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, IC50 About 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in models of neuronal injury and demyelination, binds to N-terminal RGMa, blocks BMP signaling, and lacks RGMc cross-reactivity. Elezanumab has neuroregenerative and neuroprotective activity and has no effect on iron metabolism
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
150 kDa
Dry ice
1791416-49-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
ABT-555
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q96B86
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
RGMA
Please avoid freeze-thaw cycles.